Abstract
Much interest has developed recently in the use of differentiating agents in the management of solid tumors, specifically prostate cancer. Two classes of drugs that have shown particularly intriguing results are vitamin D 3 and its analogs and the peroxisome proliferator-activated receptor gamma (PPARγ) ligands. Both the vitamin D 3 receptor and the PPARs are members of the nuclear receptor superfamily of ligand-dependent transcription factors and both are widely expressed by prostate cancer cells. This article reviews in detail the preclinical and clinical data available supporting the use of these agents in the treatment of prostate cancer. The proposed mechanisms of action of these agents and potential future therapeutic roles for these drugs are discussed as well.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
